Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-29T16:49:25.265Z Has data issue: false hasContentIssue false
  • English
  • Français

Restless Legs Syndrome and Drug-Induced Akathisia in Headache Patients

Published online by Cambridge University Press:  07 November 2014

William B. Young ,
Elcio J. Piovesan  and
Kevin M. Biglan
Get access Rights & Permissions [Opens in a new window]

Abstract

The purpose of the research presented in this article was to characterize restless legs syndrome (RLS) in a headache population and correlate treatment induced risks with dopamine blockers. Fifty patients with severe headache who were admitted to an outpatient infusion center were enrolled. The diagnosis of RLS was established using the International Restless Legs Syndrome Study Group criteria. Patients were screened for baseline akathisia using an akathisia scale and reexamined for akathisia after receiving intravenous infusion with one of four dopamine receptor blocking agents as treatment for their headaches. A change from baseline to post-infusion assessment of two points on a global assessment of akathisia was considered positive for drug-induced akathisia. Our results indicated that 41 (82%) of patients had episodic or chronic migraine. The rest had new daily persistent headache, cluster, or posttraumatic headache. Seventeen subjects (34%) met the criteria for RLS. Nineteen (38%) of the subjects developed drug-induced akathisia. Thirteen (76.5%) of the subjects with RLS developed akathisia compared with only 6 of the 33 (18.2%) without RLS (P<.0001). Finally, we concluded that headache patients with RLS are at a greatly increased risk of developing drug-induced akathisia when treated with intravenous dopamine receptor blocking agents.

Type
Original Research
Information
CNS Spectrums , Volume 8 , Issue 6: Migraines: Neurological and Psychiatric Perspectives , June 2003 , pp. 450 - 456
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Walters, AS. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634–642.CrossRefGoogle Scholar
2.Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676.CrossRefGoogle ScholarPubMed
3.Lavigne, GJ, Montplaisir, JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994;17:739–743.Google ScholarPubMed
4.Ondo, W, Jankovic, J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47:1435–1441.CrossRefGoogle ScholarPubMed
5.Chokroverty, S. Sleep disorders. In: Bradley, WG, Daroff, RB, Fenichel, GM, Marsden, CD, eds. Neurology in Clinical Practice. 3rd ed. Boston, Mass: Butterworth-Heinemann; 2000:1781–1827.Google Scholar
6.Brodeur, C, Montplaisir, J, Godbout, R, Marinier, R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology. 1988;38:1845–1848.CrossRefGoogle ScholarPubMed
7.Walters, AS, Hening, JW, Kavey, N, Chokroverty, S, Frank, SG. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol. 1988;24:455–458.CrossRefGoogle ScholarPubMed
8.Trenkwalder, C, Stiasny, K, Pollmacher, T, et al.L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trail. Sleep. 1995;18:681–688.CrossRefGoogle Scholar
9.Wetter, TC, Stiasny, K, Winkelmann, J, et al.A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 1999;52:944–950.CrossRefGoogle ScholarPubMed
10.Montplaisir, J, Nicolas, A, Denesle, R, Mancilla, BG. Restless legs syndrome improved by pramipexole: a double-blind randomized trail. Neurology. 1999;52:938–943.CrossRefGoogle Scholar
11.Reuter, I, Ellis, CM, Chaudhuri, KR. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. 1999;100:163–167.CrossRefGoogle ScholarPubMed
12.Ondo, W. Ropinirole for restless legs syndrome. Mov Disord. 1999;14:138–140.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
13.Inoue, Y, Mitani, H, Nanba, K, Kawahara, R. Treatment of periodic leg movements disorder and restless legs syndrome with talipexole. Psychiatr Clin Neurosci. 1999;53:283–285.CrossRefGoogle ScholarPubMed
14.Turjanski, N, Lees, AJ, Brooks, DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 1999;52:932–937.CrossRefGoogle ScholarPubMed
15.O'keeffe, ST, Gavin, K, Lavan, JN. Iron status and restless legs syndrome in the elderly. Age Aging. 1994;23:200–203.CrossRefGoogle ScholarPubMed
16.Sachdev, P. The neuropsychiatry of brain iron. J Neuropsychiatr Clin Neurosci. 1993;5:18–29.Google ScholarPubMed
17.Allen, RP, Mignot, E, Ripley, B, Nishino, S, Earley, CJ. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59:639–641.CrossRefGoogle ScholarPubMed
18.Ulfberg, J, Nystrom, B, Carter, N, Edling, C. Restless legs syndrome among working-aged women. Eur Neurol. 2001;46:17–19.CrossRefGoogle ScholarPubMed
19.Peres, MF, Young, WB, Kaup, AO, Zukerman, E, Silberstein, SD. Fibromyalgia Is Common In Patients With Transformed Migraine. Neurology. 2001;57:1326–1328.CrossRefGoogle ScholarPubMed
20.Yunus, MB. Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome. Baillieres Clin Rheumatol. 1994;8:811–837.CrossRefGoogle ScholarPubMed
21.Yunus, MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other similar maladies. J Indian Rheum Assoc. 2000;8:27–33.Google Scholar
22.Yunus, MB. A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheumatic Dis Clin N Am. 2002;28.Google Scholar
23.Paiva, T, Farinha, A, Martins, A, Batista, A, Guilleminault, C. Chronic headaches and sleep disorders. Arch Intern Med. 1997;157:1701–1705.CrossRefGoogle ScholarPubMed
24.Barnes, TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev. 1987;5:301–319.Google ScholarPubMed
25.Miller, CH, Mohr, F, Umbricht, D, Woerner, M, Fleischhacker, WW, Lieberman, JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59:69–75.CrossRefGoogle ScholarPubMed
26.Kurzthaler, I, Hummer, M, Kohl, C, Miller, C, Fleischhacker, WW. Propranolol treatment of olanzapine-induced akathisia. Am J Psychiatry. 1997;154:1316.Google ScholarPubMed
27.Beasley, CM, Tollefson, G, Tran, P, Satterlee, W, Sanger, T, Hamilton, S. Olanzapine versus placebo and haloperidol: acute phase results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology. 1996;14:111–123.CrossRefGoogle ScholarPubMed
28.Kurz, M, Hummer, M, Oberbauer, H, Fleischhacker, WW. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology. 1995;118:52–56.CrossRefGoogle ScholarPubMed
29.Miller, CH, Hummer, M, Oberbauer, H, Kurzthaler, I, Fleischhacker, WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacology. 1997;7:51–55.CrossRefGoogle ScholarPubMed
30.Osswald, GM, Karlssen, P, Udnaes, MH, Farde, L. Influence of the rate of administration of raclopride on akathisia and prolactin response. Psychopharmacology. 1994;114:248–256.CrossRefGoogle Scholar
31.Farde, L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans—a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology. 1992;107:23–29.CrossRefGoogle ScholarPubMed
32.Nordstrom, AL, Farde, L, Halldin, C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology. 1992;106:433–438.CrossRefGoogle ScholarPubMed
33.Barnes, TR, Braude, WM, Hill, DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2:48–49.CrossRefGoogle ScholarPubMed
34.Sachdev, P, Loneragran, C. The present status of akathisia. J Nerv Ment Dis. 1991;179:381–389.CrossRefGoogle ScholarPubMed
35.Lipinski, JF, Mallya, G, Zimmerman, P, Pope, HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339–342.Google ScholarPubMed
36.Braude, WM, Barnes, TR, Gore, SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139–150.CrossRefGoogle ScholarPubMed
37.Riley, DE, Lang, AE. Movement disorders. In: Bradley, WG, Daroff, RB, Fenichel, GM, Marsden, CD, eds. Neurology in Clinical Practice. 3rd ed. Boston, Mass: Butterworth-Heinemann; 2000:1921–1924.Google Scholar
38.vanPutten, T, May, PR, Marder, SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry. 1984;41:1036–1039.Google Scholar
39.Wang, SJ, Silberstein, SD, Young, WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997;37:377–382.CrossRefGoogle ScholarPubMed
40.Richman, PB, Allegra, J, Eskin, B, et al.A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med. 2002;20:39–42.CrossRefGoogle ScholarPubMed
41.Coppola, M, Yealy, DM, Leibold, RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541–546.CrossRefGoogle ScholarPubMed
42.Tek, DS, McClellan, DS, Olshaker, JS, Allen, CL, Arthur, DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083–1087.CrossRefGoogle ScholarPubMed
43.Cameron, JD, Lane, PL, Speechley, M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995;2:597–602.CrossRefGoogle ScholarPubMed
44.Fisher, H. A new approach to emergency department therapy of migraine headache. J Emerg Med. 1995;136:119–122.CrossRefGoogle Scholar
45.Ekbom, KA. Restless legs syndrome. Neurology. 1960;10:868–873.CrossRefGoogle ScholarPubMed
46.Peroutka, SJ. Dopamine and migraine. Neurology. 1997;49:650–656.CrossRefGoogle ScholarPubMed
47.Peroutka, SJ, Wilhoit, T, Jones, K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology. 1997;49:201–206.CrossRefGoogle Scholar
48.Mascia, A, Afra, J, Schoenen, J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia. 1998;18:174–182.CrossRefGoogle Scholar
49.Kraus, T, Schuld, A, Pollmacher, T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol. 2000;19:478–479.CrossRefGoogle Scholar
50.Horiguchi, J, Yamashita, H, Mizuno, S, et al.Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999;14:33–36.Google ScholarPubMed
51.Walters, AS, Hening, W, Rubinstein, M, Chokroverty, S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991;14:339–345.Google ScholarPubMed
52.Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538–544.CrossRefGoogle ScholarPubMed
53.Miller, CH, Fleischhacker, WW, Ehrmann, H, Kane, JM. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull. 1990;26:373–376.Google ScholarPubMed
54.Fuentenebro, FS, Huidobro, A, Rivas, AT. Restless legs syndrome and paroxetine. Acta Psychiatr Scand. 1996;94:482–484.CrossRefGoogle Scholar
55.Diamond, BI, Borison, RL. Enkephalins and nigrostriatal function. Neurology. 1978;28:1085–1088.CrossRefGoogle ScholarPubMed
56.Hening, WA, Walters, A, Kavey, N, Frank, SG, Cote, L, Fahn, S. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology. 1986;36:1363–1366.CrossRefGoogle ScholarPubMed
57.Walters, A, Hening, W, Chokroverty, S, Fahn, S. Opioid responsiveness in patients with neuroleptic induced akathisia. Mov Disord. 1986;1:119–128.CrossRefGoogle ScholarPubMed
58.Drake, M. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg. 1988;90:151–154.CrossRefGoogle ScholarPubMed
59.Adler, CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol. 1997;20:148–151.CrossRefGoogle ScholarPubMed
60.Sachdev, P, Loneragran, C. Intravenous benztropine and propranolol challenges in tardive akathisia. Psycopharmacology. 1993;113:119–122.CrossRefGoogle ScholarPubMed
61.Sachdev, P, Loneragran, C. Intravenous benztropine and propranolol challenges in acute neuroleptic induced akathisia. Clin Neuropharmacol. 1993;16:324–331.CrossRefGoogle ScholarPubMed
62.Rosebush, PI, Mazurek, MF. Complicating factors in the analysis of acute druginduced akathisia. Arch Gen Psychiatry. 1995;52:878–880.CrossRefGoogle ScholarPubMed
63.Fleischhacker, WW, Roth, SD, Kane, JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol. 1990;10:12–21.CrossRefGoogle ScholarPubMed
64.Adler, LA, Angrist, B, Fritz, P, Rotrosen, J, Mallya, G, Lipinski, JF. Lack of efficacy of d-propranolol in neuroleptic induced akathisia. Neuropsychopharmacology. 1991;4:109–115.Google ScholarPubMed
65.Miller, CH, Fleischhacker, WW. Managing antipsychotic induced acute and chronic akathisia. Drug Safety. 2000;22:73–81.CrossRefGoogle ScholarPubMed
66.Chouinard, G, Jones, B, Remington, G, et al.A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25–40.CrossRefGoogle ScholarPubMed
67.Hudson, JI, Pope, HG Jr.Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry. 1990;147:552–564.Google ScholarPubMed
68.Jacome, DE. Blepharoclonus, pseudoasterixis, and restless feet. Am J Med Sci. 2001;322:137–140.CrossRefGoogle ScholarPubMed
69.Jacome, DE. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology. 2002;58:1316.CrossRefGoogle Scholar